CA3233893A1 - Il-2 prodrug - Google Patents

Il-2 prodrug Download PDF

Info

Publication number
CA3233893A1
CA3233893A1 CA3233893A CA3233893A CA3233893A1 CA 3233893 A1 CA3233893 A1 CA 3233893A1 CA 3233893 A CA3233893 A CA 3233893A CA 3233893 A CA3233893 A CA 3233893A CA 3233893 A1 CA3233893 A1 CA 3233893A1
Authority
CA
Canada
Prior art keywords
fold
tumor
prodrug
inducible
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3233893A
Other languages
English (en)
French (fr)
Inventor
Jose Andres Salmeron-Garcia
William Winston
Daniel Hicklin
Cynthia Seidel-Dugan
Heather BRODKIN
Christopher NIRSCHL
Tiziana CAFARELLI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Werewolf Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3233893A1 publication Critical patent/CA3233893A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA3233893A 2021-10-08 2022-10-07 Il-2 prodrug Pending CA3233893A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163253964P 2021-10-08 2021-10-08
US63/253,964 2021-10-08
US202163290941P 2021-12-17 2021-12-17
US63/290,941 2021-12-17
US202263328524P 2022-04-07 2022-04-07
US63/328,524 2022-04-07
PCT/US2022/077772 WO2023060242A1 (en) 2021-10-08 2022-10-07 Il-2 prodrug

Publications (1)

Publication Number Publication Date
CA3233893A1 true CA3233893A1 (en) 2023-04-13

Family

ID=83978868

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3233893A Pending CA3233893A1 (en) 2021-10-08 2022-10-07 Il-2 prodrug

Country Status (6)

Country Link
US (1) US20240374687A1 (https=)
EP (1) EP4412712A1 (https=)
JP (1) JP2024538707A (https=)
KR (1) KR20240082401A (https=)
CA (1) CA3233893A1 (https=)
WO (1) WO2023060242A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025250977A1 (en) * 2024-05-31 2025-12-04 Werewolf Therapeutics, Inc. Cancer therapy using il-2 prodrug
WO2026072455A1 (en) * 2024-09-26 2026-04-02 Werewolf Therapeutics, Inc. Single domain human serum albumin antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210130430A1 (en) * 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes

Also Published As

Publication number Publication date
EP4412712A1 (en) 2024-08-14
WO2023060242A1 (en) 2023-04-13
US20240374687A1 (en) 2024-11-14
KR20240082401A (ko) 2024-06-10
JP2024538707A (ja) 2024-10-23

Similar Documents

Publication Publication Date Title
Zhang et al. Low-dose IL-2 therapy in autoimmune diseases: An update review
US11963980B2 (en) Activated CD26-high immune cells and CD26-negative immune cells and uses thereof
KR20210031479A (ko) Cd137 및 ox40에 결합하는 항체 분자
US20180044428A1 (en) Compositions and methods for enhancing the efficacy of cancer therapy
TW201827455A (zh) 用於治療癌症之表現膜錨定il-12之t細胞
US20220008515A1 (en) Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
US20240374687A1 (en) Il-2 prodrug
US20240010976A1 (en) Methods and compositions for stimulating gamma delta t cells
WO2021068196A1 (en) Methods of using il-33 protein in treating cancers
JP2024542159A (ja) Ｎｋ細胞と多重特異性エンゲージャーとによるがんの処置
US20260048084A1 (en) Methods of administering natural killer cells comprising an anti-human epidermal growth factor receptor 2 (her2) chimeric antigen receptor (car)
CN116744940A (zh) 用于治疗癌症的治疗性rna
CN108778312B (zh) 使用基于细胞的疗法治疗癌症和传染病的方法
KR20240099228A (ko) 조작된 nk 세포 및 이의 용도
JP2023550685A (ja) 扁平上皮癌を治療するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト
US20240415828A1 (en) Tlr7 agonist and combinations for cancer treatment
HK40119904A (zh) 含有抗人表皮生长因子受体2(her2)嵌合抗原受体(car)的自然杀伤细胞的给药方法
Moon Development of an IL12 Prodrug to Treat Solid Tumors with Minimal Toxicity
Nirschl et al. Discovery of a Conditionally Activated Interleukin-2 that Promotes Anti-tumor Immunity and Induces Tumor Regression
JP2023550880A (ja) 非黒色腫皮膚癌を治療するためのＩＬ－２／ＩＬ－１５Ｒβγアゴニスト

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240913

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240913

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240913

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20241003

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250915

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250915